Precigen, Inc

Quick facts

Marketed products

• Zopapogene imadenovec (Zopa) · Oncology
  Zopapogene imadenovec is an oncolytic adenovirus engineered to express an immunostimulatory transgene that replicates in tumor cells and triggers anti-tumor immune responses.

Phase 2 pipeline

• Pembrolizumab alone
• PRGN-2009 plus Pembrolizumab

Phase 1 pipeline

• PRGN-2012 - Phase I; Dose Level 1
• PRGN-2012 - Phase I; Dose Level 2
• PRGN-2012 - Phase II; Dose Level 2
• PRGN-3005 UltraCAR-T cells
• PRGN-3006 T Cells

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Precigen, Inc portfolio CI brief
• Precigen, Inc pipeline updates RSS